D. Norval

Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.

A. Muraro, M. Fernández-Rivas, K. Beyer, 2020, The Lancet. Child & adolescent health.

Identification of the most prevalent symptoms and sites of pain experienced by AIDS patients at Soweto Hospice, Johannesburg, South Africa

D. Norval, 2003 .

Symptoms and sites of pain experienced by AIDS patients.

D. Norval, 2004, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

Post hoc analysis examining symptom severity reduction and symptom absence during food challenges in individuals who underwent oral immunotherapy for peanut allergy: results from three trials

L. Klimek, S. Butovas, K. Beyer, 2023, Allergy, Asthma & Clinical Immunology.

Safety of Peanut (Arachis hypogaea) Allergen Powder-dnfp in Children and Teenagers With Peanut Allergy: A Pooled Summary of Phase 3 and Extension Trials.

T. Casale, A. Burks, B. Vickery, 2021, The Journal of allergy and clinical immunology.

Children and caregiver proxy quality of life from peanut oral immunotherapy trials

A. Muraro, Julie Wang, A. Vereda, 2022, Clinical and translational allergy.